These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 15699107)

  • 1. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
    Dissanayake SK; Tuera N; Ostrand-Rosenberg S
    J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo.
    Qi L; Rojas JM; Ostrand-Rosenberg S
    J Immunol; 2000 Nov; 165(10):5451-61. PubMed ID: 11067897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
    Ilkovitch D; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines.
    Dolan BP; Phelan TP; Ilkovitch D; Qi L; Wade WF; Laufer TM; Ostrand-Rosenberg S
    J Immunol; 2004 Jan; 172(2):907-14. PubMed ID: 14707062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Processing of endogenously synthesized hen egg-white lysozyme retained in the endoplasmic reticulum or in secretory form gives rise to a similar but not identical set of epitopes recognized by class II-restricted T cells.
    Adorini L; Guéry JC; Fuchs S; Ortiz-Navarrete V; Hämmerling GJ; Momburg F
    J Immunol; 1993 Oct; 151(7):3576-86. PubMed ID: 7690807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system.
    Oxenius A; Bachmann MF; Ashton-Rickardt PG; Tonegawa S; Zinkernagel RM; Hengartner H
    Eur J Immunol; 1995 Dec; 25(12):3402-11. PubMed ID: 8566030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.
    Frauwirth K; Shastri N
    Immunology; 2001 Apr; 102(4):405-15. PubMed ID: 11328374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent.
    Tewari MK; Sinnathamby G; Rajagopal D; Eisenlohr LC
    Nat Immunol; 2005 Mar; 6(3):287-94. PubMed ID: 15711549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of HLA-DM transfection on hen egg lysozyme presentation by T2.Ak cells.
    Albert LJ; Ghumman B; Watts TH
    J Immunol; 1996 Sep; 157(6):2247-55. PubMed ID: 8805621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.
    Qi L; Ostrand-Rosenberg S
    Traffic; 2000 Feb; 1(2):152-60. PubMed ID: 11208095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell.
    Lombard-Platlet S; Bertolino P; Deng H; Gerlier D; Rabourdin-Combe C
    Immunology; 1993 Dec; 80(4):566-73. PubMed ID: 7508420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The extracellular domains of MHC class II molecules determine their processing requirements for antigen presentation.
    Kjer-Nielsen L; Perera JD; Boyd LF; Margulies DH; McCluskey J
    J Immunol; 1990 Apr; 144(8):2915-24. PubMed ID: 1969876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Processing and MHC class II presentation of exogenous soluble antigen involving a proteasome-dependent cytosolic pathway in CD40-activated B cells.
    Becker HJ; Kondo E; Shimabukuro-Vornhagen A; Theurich S; von Bergwelt-Baildon MS
    Eur J Haematol; 2016 Aug; 97(2):166-74. PubMed ID: 26561366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins.
    Sanderson S; Frauwirth K; Shastri N
    Proc Natl Acad Sci U S A; 1995 Aug; 92(16):7217-21. PubMed ID: 7638170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
    Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The class II MHC-restricted presentation of endogenously synthesized ovalbumin displays clonal variation, requires endosomal/lysosomal processing, and is up-regulated by heat shock.
    Michalek MT; Benacerraf B; Rock KL
    J Immunol; 1992 Feb; 148(4):1016-24. PubMed ID: 1737924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.